The Bullseye Now Turns To Microsoft Corporation (MSFT), Boston Scientific Corporation (BSX) - The RNS Daily

A look at MSFT technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 44.76 point. Its trading volume has lost -5038265 shares compared to readings over the past three months as it recently exchanged 36101735 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 41140000 shares, and this is 0.88 times the normal volume.

Microsoft Corporation (NASDAQ:MSFT) dipped by -12.53% over the past three months which led to its overall six-month increase to stand at 1.11%. The equity price rose 7.43% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a -8.23% fall over the past 30 days. Over the past 12 months the stock has embarked on a rally that has seen it rise 18.21% and is now down by -0.44% since start of this year.

The shares of Microsoft Corporation dropped by -12.96% or -$15.06 from its last recorded high of $116.18 which it attained on October 03 to close at $101.12 per share. Over the past 52 weeks, the shares of Microsoft Corporation has been trading as low as $83.83 before witnessing a massive surge by 20.63% or $17.29. This price movement has led to the MSFT stock receiving more attention and has become one to watch out for. It dipped by -0.44% on Wednesday and this got the market worried. The stock’s beta now stands at 1.2 and when compared to its 200-day moving average and its 50-day moving average, MSFT price stands -2.28% below and -4.67% below respectively. Its average daily volatility for this week is 3.97% which is more than the 3.74% recorded over the past month.

Experts from research firms are bullish about the near-term performance of Microsoft Corporation (MSFT) with most of them predicting a $125.39 price target on a short-term (12 months) basis. The average price target by the analysts will see a 24% rise in the stock and would lead to MSFT’s market cap to surge to $1004.37B. The stock has been rated an average 1.6, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 33 analysts that track Microsoft Corporation (NASDAQ:MSFT) and find out that 1 of them rated it as a Hold. 31 of the 32 analysts rated it as a Buy or a Strong Buy while 1 advised investors to desist from buying the stock or sell it if they already possess it.

The price of Boston Scientific Corporation (NYSE:BSX) currently stands at $34.46 after it went down by $-0.88 or -2.49% and has found a strong support at $34.06 a share. If the BSX price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $33.66 mark would also be bad for the stock as it means that the stock would plunge by 2.32% from its current position. However, if the stock price is able to trade above the resistance point around $34.86, then it could likely surge higher to try and break the upward resistance which stands at $35.26 a share. Its average daily volatility over the past one month stands at 3.49%. The stock has plunged by 1.16% from its 52-weeks high of $34.06 which it reached on Oct. 02, 2018. In general, it is 27.92% above its 52-weeks lowest point which stands at $24.84 and this setback was observed on Feb. 09, 2018.

Analysts have predicted a price target for Boston Scientific Corporation (BSX) for 1 year and it stands at an average $41.71/share. This means that it would likely increase by 21.04% from its current position. The current price of the stock has been moving between $34.06 and $34.86. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $26. On the other hand, one analyst is super bullish about the price, setting a target as high as $48.

The BSX stock Stochastic Oscillator (%D) is at 88.15%, which means that it is currently overbought and its prices could dip very soon. The shares P/S ratio stands at 5.1 which compares to the 11.09 recorded by the industry or the 21.76 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 21.85, which is lower than the 31.59 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 17.5% over the past five years.

Analysts view Boston Scientific Corporation (NYSE:BSX) as a Buy, with 1.5 consensus rating. Reuters surveyed 22 analysts that follow BSX and found that 2 of those analysts rated the stock as a Hold. The remaining 20 were divided, with 20 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Boston Scientific Corporation (BSX) shares or sell it if they already own it.

Let's block ads! (Why?)